Cara Therapeutics: Scratching An Itch Left Unscratched | Latest News RSS feed

Cara Therapeutics: Scratching An Itch Left Unscratched - Latest News


Cara Therapeutics: Scratching An Itch Left Unscratched

CARA therapeutics wholly owns its proprietary kappa opioid-receptor agonist, KORSUVA/CR845, and is targeting several largely underserved markets. Several catalysts are expected throughout the next yea... read more

Why Cara Therapeutics Shares Jumped 10% Today

Cara Therapeutics' treatment for chronic kidney disease-associated itching in dialysis patients. Since the news was reported, Cara Therapeutics shares have risen from less than $12 per share to over $... read more

Is Cara Therapeutics, Inc. a Buy?

An investment in the volatile Cara Therapeutics is essentially a bet on a single drug for pain, itching, and inflammation that the company has in human trials, CR845. The reliance on a single molecule ... read more

Looking for another news?


Forget Amgen -- Cara Therapeutics, Inc. Is a Better Growth Stock

Cara Therapeutics' (NASDAQ: CARA ... Around 60% of all patients on hemodialysis experience the itching associated with CKD-aP. While Cara looks forward to potentially launching its first product over ... read more

Jetpack

3 Biotech Stocks I'd Buy Right Now

... of around 4.2 million patients with various kidney disorders suffer from chronic itching and are underserved by existing treatments. Later this year, Cara Therapeutics intends to begin a study tha... read more

Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

March 15, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq ... In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant impr... read more

3 Growth Stocks for Forward-Looking Investors

Cara Therapeutics stock rose sharply when IV CR845 became the first drug to significantly reduce chronic itching symptoms common among dialysis patients. Investors can look forward to several big cata... read more

Why 2018 Could Be the Best Year Yet for Cara Therapeutics

But for Cara Therapeutics (NASDAQ: CARA ... plans to conduct two late-stage clinical trials of IV CR845 in treating moderate to severe pruritis (itching) in patients on dialysis. The first of these sh... read more

Cara Therapeutics Wins Big on FDA Breakthrough

Cara Therapeutics Inc. (CARA) saw its shares make a handy gain ... Part A of the trial met its primary endpoint, with a 68% reduction in worst itching scores versus placebo after an eight-week treatme... read more

3 Biotech Stocks I'd Buy Right Now

... of around 4.2 million patients with various kidney disorders suffer from chronic itching and are underserved by existing treatments. Later this year, Cara Therapeutics intends to begin a study tha... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us